Latest Earnings Results: Q2 '26
Estimated EPS
-$0.38
Reported EPS
-$0.35
Surprise
+7.28%
Estimated Rev
$0M
Reported Rev
---
Surprise
---
• Reported GAAP EPS of -$0.35 up 55.13% YoY • PolyPid expects to submit a Marketing Authorization Application to the European Medicines Agency during the third quarter of 2026, with a potential U.S. commercial launch of D-PLEX100 targeted for early 2027.
Bullish Takeaway
PolyPid achieved significant regulatory and commercial progress, including FDA Priority Review for D-PLEX100 and a lucrative partnership with Azurity Pharmaceuticals, while continuing to advance its proprietary Kynatrix technology pipeline programs.
Bearish Takeaway
PolyPid continues to report significant net losses and an accumulated deficit, while maintaining a reduced cash position compared to year-end 2025, subject to inherent risks and uncertainties regarding future performance.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.40 | -- | -- | N/A |
Q2 '26 | -$0.38 | -$0.35 | 7.28% | BEAT |
Q1 '26 | -$0.43 | -$0.35 | 19.23% | BEAT |
Q4 '25 | -$0.33 | -$0.41 | -24.24% | MISSED |
Q3 '25 | -$0.52 | -$0.37 | 29.19% | BEAT |